NDAORALTABLET
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HARMONYL (deserpidine) is an oral antihypertensive tablet approved in 1957 that belongs to the rauwolfia alkaloid class of medications. It is used to treat hypertension by reducing blood pressure through sympathetic nervous system inhibition. The drug represents a legacy therapeutic approach to blood pressure management largely superseded by modern antihypertensive classes.
LOE Approaching
Product is in late-stage lifecycle with minimal commercial momentum; brand team is likely small and focused on legacy patient maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HARMONYL offers minimal career growth potential given its LOE-approaching status, zero linked job openings, and lack of commercial momentum. Professionals on this brand should view the role as a maintenance position and actively plan transition to growth-stage products within the AbbVie portfolio.
Brand Manager (Legacy)Field Sales Representative
Worked on HARMONYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.